Societal CDMO (Societal CDMO) Cash-to-Debt : 0.19 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Societal CDMO Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Societal CDMO's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.19.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Societal CDMO couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Societal CDMO's Cash-to-Debt or its related term are showing as below:

SCTL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17 Med: 0.47 Max: No Debt
Current: 0.19

During the past 13 years, Societal CDMO's highest Cash to Debt Ratio was No Debt. The lowest was 0.17. And the median was 0.47.

SCTL's Cash-to-Debt is ranked worse than
77% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.945 vs SCTL: 0.19

Societal CDMO Cash-to-Debt Historical Data

The historical data trend for Societal CDMO's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Societal CDMO Cash-to-Debt Chart

Societal CDMO Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.17

0.22

0.24

0.34

0.19

Societal CDMO Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															0.34	0.14	0.11	0.19	0.19

Competitive Comparison of Societal CDMO's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Societal CDMO's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Societal CDMO's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Societal CDMO's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Societal CDMO's Cash-to-Debt falls into.

Societal CDMO Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Societal CDMO's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	8.095	/	(37.861	+	4.492)
	=	0.19

Societal CDMO's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	8.095	/	(37.861	+	4.492)
	=	0.19

Societal CDMO (NAS:SCTL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Societal CDMO Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Societal CDMO's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Societal CDMO (Societal CDMO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Societal CDMO Inc (NAS:SCTL) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 E. Uwchlan Avenue, Suite 112, Exton, PA, USA, 19341

Website

https://www.societalcdmo.com

Societal CDMO Inc is a bi-coastal contract development and manufacturing organization. It offers capabilities spanning pre-Investigational New Drug development to commercial manufacturing and packaging for a wide range of therapeutic dosage forms primarily focused on small molecules. The company also provides therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging, and logistics services to the global pharmaceutical market.

Executives

Bryan M. Reasons	director	C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Elena Cant	director	C/O SOCIETAL CDMO, INC., 1 E. UWCHLAN AVENUE, SUITE 112, EXTON PA 19341
Enloe J David Jr	director, officer: Chief Executive Officer
James Charles Miller	director	490 LAPP ROAD, MALVERN PA 19355
Wayne Weisman	director	490 LAPP ROAD, MALVERN PA 19355
William Ashton	director	C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Winston J Churchill	director	C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
Awm Investment Company, Inc.	10 percent owner	527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Mathew Paul Arens	director, 10 percent owner	C/O FIRST LIGHT ASSET MANAGEMENT, LLC, 3300 EDINBOROUGH WAY, SUITE 201, EDINA MN 55435
First Light Asset Management, Llc	director, 10 percent owner	3300 EDINBOROUGH WAY, SUITE 201, EDINA MN 55435
Laura L. Parks	director	C/O RECRO PHARMA, INC., 490 LAPP ROAD, MALVERN PA 29355
Michael Berelowitz	director	415 EAST 37TH STREET, APT 36C, NEW YORK NY 10016
Ryan David Lake	officer: Chief Financial Officer	KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Scp Vitalife Partners (israel) Ii, L.p.	10 percent owner	SUITE 190, 7 GREAT VALLEY PARKWAY, MALVERN PA 19355
Scp Vitalife Partners Ii Lp	10 percent owner	SUITE 190, 7 GREAT VALLEY PARKWAY, MALVERN PA 19355